Focused On-demand Library for RNA helicase Mov10l1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Moloney leukemia virus 10-like protein 1

Alternative UPACC:

Q9BXT6; A7E211; A8MXC6; B7WPP1; B7Z7R1; F5H403; Q5TGD5; Q8NBD4; Q9NXW3; Q9UFB3; Q9UGX9


RNA helicase Mov10l1, also known as Moloney leukemia virus 10-like protein 1, plays a pivotal role in spermatogenesis. It represses transposable elements, preserving germline integrity through the piRNA metabolic process. This involves forming complexes with piRNAs and Piwi proteins, crucial for transposon methylation and repression. Mov10l1's ATP-dependent RNA helicase activity is essential, unwinding RNA to facilitate piRNA precursor processing.

Therapeutic significance:

Given its critical function in spermatogenesis, Mov10l1's association with Spermatogenic failure 73, a male infertility disorder due to meiotic arrest, underscores its therapeutic potential. Understanding Mov10l1's role could unveil novel strategies for treating infertility.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.